Your browser doesn't support javascript.
loading
Alzheimer's disease-related biomarkers and cancer-related cognitive decline: the thinking and living with cancer study.
Mandelblatt, Jeanne; Dage, Jeffrey L; Zhou, Xingtao; Small, Brent J; Ahles, Tim A; Ahn, Jaeil; Artese, Ashley; Bethea, Traci N; Breen, Elizabeth C; Carroll, Judith E; Cohen, Harvey J; Extermann, Martine; Graham, Deena; Isaacs, Claudine; Jim, Heather S L; Mcdonald, Brenna C; Nakamura, Zev M; Patel, Sunita K; Rebeck, G William; Rentscher, Kelly E; Root, James C; Russ, Kristen A; Tometich, Danielle B; Turner, R Scott; Van Dyk, Kathleen; Zhai, Wanting; Huang, Li-Wen; Saykin, Andrew J.
Afiliação
  • Mandelblatt J; Georgetown Lombardi Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
  • Dage JL; Stark Neurosciences Research Institute, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Zhou X; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.
  • Small BJ; School of Aging Studies, University of South Florida, and Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL, USA.
  • Ahles TA; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ahn J; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.
  • Artese A; Department of Exercise Science and Health Promotion, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL, USA.
  • Bethea TN; Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
  • Breen EC; Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
  • Carroll JE; Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Cohen HJ; Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
  • Extermann M; Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA, USA.
  • Graham D; Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA.
  • Isaacs C; Senior Adult Oncology Program, Department of Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
  • Jim HSL; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
  • Mcdonald BC; Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC, USA.
  • Nakamura ZM; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
  • Patel SK; Department of Radiology and Imaging Sciences, Melvin and Bren Simon Comprehensive Cancer Center, and Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Rebeck GW; Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Rentscher KE; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Root JC; Department of Neuroscience, Georgetown University, Washington, DC, USA.
  • Russ KA; Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Tometich DB; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Turner RS; Department of Medical and Molecular Genetics and National Centralized Repository for Alzheimer's and Related Dementias, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Van Dyk K; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
  • Zhai W; Department of Neurology, Georgetown University, Washington, DC, USA.
  • Huang LW; Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
  • Saykin AJ; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
J Natl Cancer Inst ; 2024 May 24.
Article em En | MEDLINE | ID: mdl-38788675
ABSTRACT

PURPOSE:

We evaluated whether plasma Alzheimer's Disease (AD)-related biomarkers were associated with cancer-related cognitive decline (CRCD) among older breast cancer survivors.

METHODS:

We included survivors 60-90 years with primary stage 0-III breast cancers (n = 236) and frequency-matched non-cancer controls (n = 154) who passed a cognitive screen and had banked plasma specimens. Participants were assessed at baseline (pre-systemic therapy) and annually for up to 60-months. Cognition was measured using tests of attention, processing speed and executive function (APE) and learning and memory (LM); perceived cognition was measured by the FACT-Cog PCI. Baseline plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), beta-amyloid 42/40 (Aß42/40) and phosphorylated tau (p-tau181) were assayed using single molecule arrays. Mixed models tested associations between cognition and baseline AD-biomarkers, time, group (survivor vs control) and their two- and three-way interactions, controlling for age, race, WRAT4 Word Reading score, comorbidity and BMI; two-sided 0.05 p-values were considered statistically significant.

RESULTS:

There were no group differences in baseline AD-related biomarkers except survivors had higher baseline NfL levels than controls (p = .013). Survivors had lower adjusted longitudinal APE than controls starting from baseline and continuing over time (p = <0.002). However, baseline AD-related biomarker levels were not independently associated with adjusted cognition over time, except controls had lower APE scores with higher GFAP levels (p = .008).

CONCLUSION:

The results do not support a relationship between baseline AD-related biomarkers and CRCD. Further investigation is warranted to confirm the findings, test effects of longitudinal changes in AD-related biomarkers and examine other mechanisms and factors affecting cognition pre-systemic therapy.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article